3-Menthyloxy-propanal | 26252-26-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-Menthyloxy-propanal
• 英文别名: 3-(5-Methyl-2-propan-2-ylcyclohexyl)oxypropanal
• CAS: 26252-26-6
• 化学式: C₁₃H₂₄O₂
• 分子量: 212.332
• InChiKey: DRLUXTYRCNFKBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  薄荷脑 在 苄基三甲基氢氧化铵 作用下， 生成 3-Menthyloxy-propanal
  参考文献：
  名称：

  Griffe,A.; Arbelet,J., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1969, vol. 269, p. 989 - 991

  摘要：

  DOI：

文献信息

• Tricyclo compounds, a process for their production and pharmaceutical composition containing the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20030229115A1

  公开（公告）日：2003-12-11

  This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: 1 to a process for their reproduction, to a pharmaceutical composition containing the same and to a use thereof.

  本发明涉及用于治疗和预防移植抗拒、骨髓移植引起的移植物抗宿主病、自身免疫疾病、感染性疾病等的三环化合物，可以用以下公式表示：1，以及其复制过程、含有其的制药组合物和使用方法。
• Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
  申请人：Okuhara Masakuni

  公开号：US20050124646A1

  公开（公告）日：2005-06-09

  This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.

  本发明涉及三环化合物，其可用于治疗和预防移植耐受性、骨髓移植引起的移植物抗宿主病、自身免疫性疾病、感染性疾病等，该化合物可以用以下公式表示：本发明还涉及其制备方法、含有该化合物的药物组合物以及其用途。
• Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus of cyclosporins
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US20040092436A1

  公开（公告）日：2004-05-13

  Present invention is relating to a new use of a compound possessing an inhibitory activity on the production of nitric oxide, for increasing an effect caused by IL-2 inhibitor.

  本发明涉及一种具有抑制一氧化氮产生活性的化合物的新用途，用于增强IL-2抑制剂引起的效应。
• A pharmaceutical solution comprising derivatives of FK506
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0444659A2

  公开（公告）日：1991-09-04

  A pharmaceutical solution which contains the compound of the general formula having the immusuppreseive activity is disclosed.

  本发明公开了一种含有通式化合物的药液，该化合物具有免疫抑制活性。
• LIPOSOME PREPARATION CONTAINING TRICYCLIC COMPOUND
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0658344A1

  公开（公告）日：1995-06-21

  A liposome preparation containing, incorporated in liposome, an immunosuppressive tricyclic compound or a pharmaceutically acceptable salt thereof. Since the tricyclic compound is incorporated in liposome stably and quantitatively, a pharmaceutical preparation with an excellent persistence of drug efficacy can be provided in a wide variety of preparation forms.

  一种脂质体制剂，其中含有掺入脂质体的免疫抑制性三环化合物或其药学上可接受的盐。由于三环化合物被稳定、定量地掺入脂质体中，因此可以以多种制剂形式提供药效持久性极佳的药物制剂。